sub:assertion {
  d:DB00491 v:identifier "DB00491" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB00491" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB00491> ;
    dv:drugbank-id "APRD01117" , "DB00491" ;
    dv:x-atc <http://bio2rdf.org/atc:A10BF02> ;
    dv:x-cas <http://bio2rdf.org/cas:72432-03-2> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:390074> ;
    dv:x-kegg <http://bio2rdf.org/kegg:C07708> , <http://bio2rdf.org/kegg:D00625> ;
    dv:x-ndc <http://bio2rdf.org/ndc:0009-5012-01> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA164776726> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:441314> ;
    dv:x-pubchemsubstance <http://bio2rdf.org/pubchem.substance:46504492> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Miglitol> ;
    dct:description """Miglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body.

Miglitol inhibits glycoside hydrolase enzymes called alpha-glucosidases. Since miglitol works by preventing digestion of carbohydrates, it lowers the degree of postprandial hyperglycemia. It must be taken at the start of main meals to have maximal effect. Its effect will depend on the amount of non-monosaccharide carbohydrates in a person's diet.

In contrast to acarbose (another alpha-glucosidase inhibitor), miglitol is systemically absorbed; however, it is not metabolized and is excreted by the kidneys."""@en ;
    dct:identifier "drugbank:DB00491" ;
    dct:title "Miglitol"@en ;
    a dv:Drug ;
    rdfs:label "Miglitol [drugbank:DB00491]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB00491> , <http://www.drugs.com/cdi/miglitol.html> , <http://www.rxlist.com/cgi/generic2/miglitol.htm> .
}